H.C. Wainwright Sticks to Its Buy Rating for Sutro Biopharma (STRO)

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Sutro Biopharma (STROResearch Report) today and set a price target of $30.00. The company’s shares closed yesterday at $6.19.

According to TipRanks, Fein is an analyst with an average return of -7.2% and a 40.32% success rate. Fein covers the Healthcare sector, focusing on stocks such as Sutro Biopharma, Amylyx Pharmaceuticals Inc, and ACADIA Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sutro Biopharma with a $26.67 average price target.

See the top stocks recommended by analysts >>

The company has a one-year high of $23.70 and a one-year low of $3.33. Currently, Sutro Biopharma has an average volume of 988.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sutro Biopharma Inc. engages in the drug discovery, development and manufacturing of pharmaceutical products. Its products technologies include XpressCF, anti-body drug conjugates, bispecifics & engineered antibodies and cGMP facility. The company was founded by James R. Swartz and Sutanto Widjaja in June 2003 and is headquartered in South San Francisco, CA.

Read More on STRO:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed